Frovatriptan and Menstrual Migraine (FROVA)
We are looking for women who suffer from menstrual migraine to participate in a 2-visit migraine brain imaging research study. Our goal is to see how the menstrual migraine brain's pain pathways function when the migraineur has been taking Frovatriptan. During the screening visit (Visit 1) participants will sign the informed consent form, complete questionnaires, meet with the study physician, and have QST (quantitative sensory testing: to determine your pain thresholds for a heat stimulus) performed. For Visit 2's MRI scan, subjects will be asked to lie very still while the scan is occurring. In some parts, they will not have to do anything, while in others they will be asked to rate pain and unpleasantness for brush and thermal stimuli. Participants are compensated for both visits.
|Study Design:||Observational Model: Cohort|
|Official Title:||Mapping CNS Changes to Frovatriptan Administration in Acute Treatment of Prodrome or Preventative Treatment of Menstrual Migraine (MM)|
|Study Start Date:||April 2010|
|Study Completion Date:||May 2010|
|Primary Completion Date:||May 2010 (Final data collection date for primary outcome measure)|
All subjects will be taking Frovatriptan tablets within 48 hours prior to the scan session (Visit 2).
Please refer to this study by its ClinicalTrials.gov identifier: NCT01114711
|United States, Massachusetts|
|Neuroimaging Center, McLean Hospital|
|Belmont, Massachusetts, United States, 02478|
|Principal Investigator:||David Borsook, MD, PhD||Mclean Hospital|